Research could lead to improved diagnosis and the first effective treatment for the disorder, called “clonal hematopoiesis of indeterminate potential,” or CHIP. 

Roughly 1 in 10 people over age 70 will develop CHIP, an explosive, clonal growth of abnormal blood cells that increases risk of blood cancers and death from cardiovascular, lung and liver disease.

A U.S.-Canadian research collaboration led by Vanderbilt University Medical Center has identified common, age-associated changes in the blood as a risk factor for acute kidney injury, which occurs in more than 1 in 5 hospitalized adults worldwide.

A transcontinental research effort led by scientists from Vanderbilt University Medical Center and the University of Michigan has upended some long-standing assumptions about mutations — how often they occur, what causes them and what they do.

An international coalition of biomedical researchers co-led by Vanderbilt's Alexander Bick, MD, PhD, has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer.

Vanderbilt researchers have developed a new method to analyze mutations in blood stem cells that can trigger explosive, clonal expansions of abnormal cells.

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease